-- トレンドラインズ（SGX:42T）の子会社であるベンシカ・メディカルは、同社の薬剤送達システム「VixE」の第2相臨床試験開始について、米国食品医薬品局（FDA）の承認を取得した。シンガポール証券取引所への月曜日の提出書類で明らかになった。 医療・その他サービス企業である同社の株価は、火曜日の取引で約5%上昇した。 この針を使わない薬剤送達システムは、過活動膀胱の治療薬として開発されており、第2相試験では米国と欧州で約210人の患者を対象に試験を実施する予定だ。
Related Articles
Research
Research Alert: Ab Inbev Q1 Tops Estimates; Corona Momentum, Volume Recovery Support Outlook
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ABI reported Q1 2026 organic revenue growth of 5.8%, beating consensus of 3.0%, supported by revenue per hectoliter growth of 4.5% and a volume increase of 0.8% vs. expected decline of 0.5%. Underlying EPS of USD0.97 surpassed consensus of USD0.89 and the prior year's USD0.81, representing the highest Q1 performance in company history. We believe ABI's megabrands momentum, with combined revenues growing 8.2%, led by Corona's 16% growth outside its home market, demonstrates competitive positioning strength with market share gains in 75% of its markets. Management maintained 2026 EBITDA growth guidance of 4-8%, in line with its medium-term outlook and consensus of 5.1%, with capex expected at USD3.5-4.0B. The Beyond Beer segment accelerated with 37% revenue growth, while gross margin expanded 76 bps to 56.6% despite EBITDA margin contracting 15 bps due to increased marketing investments. We remain confident in ABI's growth trajectory given its global portfolio strength and resilient market positioning.
$BUD
Asia
Tyntek Logs About NT$17 Million in Q1 Profit; Shares Rally 10%
Tyntek (TPE:2426) posted a profit attributable to owners of NT$16.6 million, or NT$0.06 per share, for the first quarter, according to a Monday filing with the Taiwan Stock Exchange.Shares jumped 10% in Tuesday's midday trade.Meanwhile, operating revenue stood at NT$545.1 million.The chip manufacturer did not provide comparative year-ago figures.
$TPE:2426
Asia
Ambuja Cements' Consolidated Profit Jumps in Fiscal Q4; Shares Fall 3%
Ambuja Cements' (NSE:AMBUJACEM, BOM:500425) consolidated attributable profit increased to 18.3 billion Indian rupees in the fiscal fourth quarter from 10.3 billion rupees a year ago, according to a filing to the Indian stock exchanges on Monday.Shares of the cement manufacturer were down nearly 3% in Tuesday's trade.Earnings per share during the quarter ended March 31 climbed to 7.37 rupees from 4.16 rupees a year earlier.Revenue from operations in fiscal Q4 also rose year on year to 108.9 billion rupees from 98.9 billion rupees a year earlier.The company's board recommended a final dividend of 2 rupees per share for the financial year ended March 31. The dividend will be paid on or after July 1 to shareholders of record on June 12, the filing said.
$BOM:500425$NSE:AMBUJACEM